GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verastem Inc (NAS:VSTM) » Definitions » Cyclically Adjusted Price-to-FCF

Verastem (Verastem) Cyclically Adjusted Price-to-FCF : (As of May. 02, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Verastem Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Verastem Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Verastem's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verastem Cyclically Adjusted Price-to-FCF Chart

Verastem Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Verastem Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Verastem's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Verastem's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verastem's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verastem's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Verastem's Cyclically Adjusted Price-to-FCF falls into.



Verastem Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Verastem's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Verastem's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.105/129.4194*129.4194
=-1.105

Current CPI (Dec. 2023) = 129.4194.

Verastem Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -4.374 99.695 -5.678
201406 -4.263 100.560 -5.486
201409 -4.977 100.428 -6.414
201412 -4.672 99.070 -6.103
201503 -4.293 99.621 -5.577
201506 -3.949 100.684 -5.076
201509 -3.779 100.392 -4.872
201512 -3.316 99.792 -4.300
201603 -3.512 100.470 -4.524
201606 -2.170 101.688 -2.762
201609 -1.952 101.861 -2.480
201612 -1.931 101.863 -2.453
201703 -3.455 102.862 -4.347
201706 -4.697 103.349 -5.882
201709 -3.779 104.136 -4.697
201712 -5.798 104.011 -7.214
201803 -5.325 105.290 -6.545
201806 -2.133 106.317 -2.597
201809 -3.768 106.507 -4.579
201812 -5.448 105.998 -6.652
201903 -6.302 107.251 -7.605
201906 -5.632 108.070 -6.745
201909 -4.502 108.329 -5.378
201912 -5.851 108.420 -6.984
202003 -3.773 108.902 -4.484
202006 -1.636 108.767 -1.947
202009 3.163 109.815 3.728
202012 -1.532 109.897 -1.804
202103 -1.365 111.754 -1.581
202106 -0.937 114.631 -1.058
202109 -0.722 115.734 -0.807
202112 -0.685 117.630 -0.754
202203 -1.242 121.301 -1.325
202206 -0.817 125.017 -0.846
202209 -0.918 125.227 -0.949
202212 -0.975 125.222 -1.008
202303 -1.213 127.348 -1.233
202306 -1.122 128.729 -1.128
202309 -0.619 129.860 -0.617
202312 -1.105 129.419 -1.105

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Verastem  (NAS:VSTM) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Verastem Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Verastem's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Verastem (Verastem) Business Description

Industry
Traded in Other Exchanges
Address
117 Kendrick Street, Suite 500, Needham, MA, USA, 02494
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Executives
Robert E. Gagnon officer: Chief Financial Officer C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
Daniel Calkins officer: Vice President of Finance C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Brian M Stuglik director C/O VERASTEM, INC., 117, NEEDHAM MA 02494
Dan Paterson officer: Chief Operating Officer 215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Karin Anna Tollefson director C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Anil Kapur director 275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104